$4.62 Billion is the total value of Avidity Partners Management LP's 85 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CMPX | COMPASS THERAPEUTICS INC | $10,060,000 | +120.6% | 2,000,000 | 0.0% | 0.22% | +134.4% | |
| IPSC | CENTURY THERAPEUTICS INC | $6,687,468 | -48.1% | 1,303,600 | 0.0% | 0.14% | -44.7% | |
| GRPH | GRAPHITE BIO INC | $5,229,000 | +4.7% | 1,575,000 | 0.0% | 0.11% | +10.8% | |
| MSAC | MEDICUS SCIENCES ACQUISITION | $5,236,400 | +1.7% | 520,000 | 0.0% | 0.11% | +7.6% | |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $5,050,000 | +1.9% | 500,000 | 0.0% | 0.11% | +7.9% | |
| PANA | PANACEA ACQUISITION CORP II | $5,025,000 | +2.6% | 500,000 | 0.0% | 0.11% | +9.0% | |
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $3,992,000 | +0.8% | 400,000 | 0.0% | 0.09% | +6.2% | |
| SYROS PHARMACEUTICALS INC | $3,231,000 | -44.3% | 900,000 | 0.0% | 0.07% | -40.7% | ||
| CMAX | CAREMAX INC | $2,756,951 | -48.5% | 755,329 | 0.0% | 0.06% | -45.0% | |
| DNAB | SOCIAL CAP SUVRETTA HLDS CRP | $2,012,000 | +2.7% | 200,000 | 0.0% | 0.04% | +10.0% | |
| DNAD | SOCIAL CAP SUVRETTA HLDS CP | $2,010,000 | +2.3% | 200,000 | 0.0% | 0.04% | +10.0% | |
| SCYX | SCYNEXIS INC | $1,779,336 | -35.0% | 1,140,600 | 0.0% | 0.04% | -30.4% | |
| HYPERFINE INC | $1,263,153 | +3.7% | 1,503,754 | 0.0% | 0.03% | +8.0% | ||
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/202 | $5,199 | +419.9% | 57,770 | 0.0% | 0.00% | – | |
| NUVBWS | NUVATION BIO INC*w exp 07/07/202 | $14,450 | -19.7% | 99,999 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.